Related Experiment Video
Updated: Aug 7, 2026

Induction and Testing of Hypoxia in Cell Culture
Published on: August 12, 2011
Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis
Cheng-Chi Chang1, Ming-Tsai Lin, Been-Ren Lin
1Angiogenesis Research Center, Laboratory of Molecular and Cellular Toxicology, Institute of Toxicology, College of Medicine, National Taiwan University, No. 1 Sec. 1 Jen-Ai Rd., Taipei 100, Taiwan.
Background:
Connective tissue growth factor (CTGF) inhibits the metastatic activity of human lung cancer cells in a mouse model; however, the mechanism of this modulation is unclear. We investigated the role of angiogenesis in this process.
Methods:
CL1-5 and A549 human lung adenocarcinoma cells were stably transfected with vectors containing CTGF or hypoxia-inducible factor (HIF) 1alpha or with vector controls. Transfected cells were injected into nude mice (n = 10 per group), and tumor growth, metastasis, and mouse survival were measured. Excised xenograft tumors and primary human lung adenocarcinomas (n = 24) were subjected to immunohistochemistry with antibodies to the endothelial cell marker CD31 and to CTGF. Expression of HIF-1alpha and vascular endothelial growth factor (VEGF) A was assessed in vitro by using reporter gene assays. Cells were transiently transfected with HIF-1alpha mutant and antisense arrest-defective 1 protein (ARD-1), and HIF-1alpha acetylation was assayed by immunoprecipitation. All statistical tests were two-sided.
Results:
Xenograft tumors derived from CTGF transfectants grew more slowly than those from control-transfected cells and had reduced expression of HIF-1alpha and VEGF-A, vascularization (as assessed by CD31 expression), and metastasis (all P<.001). Xenograft tumors derived from CTGF-overexpressing cells that were transfected with HIF-1alpha had higher VEGF-A expression than CTGF-overexpressing xenografts. Mice with CTGF/HIF-1alpha xenografts had lower survival than mice carrying CTGF-overexpressing xenografts (CL1-5/Neo, mean = 69.6 days, 95% confidence interval [CI] = 53.9 to 85.3 days versus CL1-5/CTGF, mean = 102.1 days, 95% CI = 92.1 to 112.1 days; P = .001, CL1-5/CTGF, mean = 102.1 days, 95% CI = 92.1 to 112.1 days versus CL1-5/CTGF/HIF-1alpha, mean = 81.7 days, 95% CI = 66.5 to 96.9 days; P = .011, CL1-5/Neo, mean = 69.6 days, 95% CI = 53.9 to 85.3 days versus CL1-5/CTGF/HIF-1alpha, mean = 81.7 days, 95% CI = 66.5 to 96.9 days; P = .122). Tumors of patients with the same disease stage but with high CTGF protein expression had reduced microvessel density compared with tumors with low expression. Transfection with antisense-ARD1 decreased the level of acetylated HIF-1alpha and restored HIF-1alpha and VEGF-A expression in CTGF-overexpressing cells.
Conclusion:
CTGF inhibition of metastasis involves the inhibition of VEGF-A-dependent angiogenesis, possibly by promoting HIF-1alpha protein degradation.
Insights
Connective tissue growth factor (CTGF) inhibits lung cancer metastasis by reducing angiogenesis, potentially through promoting hypoxia-inducible factor (HIF)-1alpha degradation. This study clarifies CTGF
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Connective tissue growth factor (CTGF) is known to inhibit human lung cancer cell metastasis in mouse models.
- The precise mechanism by which CTGF modulates metastatic activity, particularly its role in angiogenesis, remains unclear.
Purpose of the Study:
- To investigate the role of angiogenesis in CTGF-mediated inhibition of lung cancer metastasis.
- To elucidate the molecular mechanisms underlying CTGF's effect on tumor growth, vascularization, and metastatic potential.
Main Methods:
- Human lung adenocarcinoma cell lines (CL1-5, A549) were transfected with CTGF or hypoxia-inducible factor (HIF)-1alpha.
- Tumor growth, metastasis, and survival were assessed in nude mouse xenograft models.
- Immunohistochemistry for CD31 (endothelial marker) and CTGF, along with in vitro reporter gene assays for HIF-1alpha and vascular endothelial growth factor (VEGF)-A, were performed.
Main Results:
- CTGF-transfected xenografts exhibited slower growth, reduced vascularization (CD31 expression), lower HIF-1alpha and VEGF-A levels, and decreased metastasis compared to controls.
- Overexpression of HIF-1alpha in CTGF-transfected cells partially restored VEGF-A expression.
- High CTGF expression in human lung adenocarcinoma tumors correlated with reduced microvessel density.
- Inhibition of ARD-1 (a protein involved in HIF-1alpha acetylation) restored HIF-1alpha and VEGF-A expression in CTGF-overexpressing cells.
Conclusions:
- CTGF inhibits lung cancer metastasis by suppressing VEGF-A-dependent angiogenesis.
- The mechanism likely involves the promotion of HIF-1alpha protein degradation, leading to reduced vascularization.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
The Tumor Microenvironment
TGF - β Signaling Pathway
Mechanism of Angiogenesis
Intracellular Signaling Affects Focal Adhesions
Some...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
